Influence of Bone Marrow Fat Embolism on Coagulation Activation in an Ovine Model of Vertebroplasty

Krebs, Jörg; Ferguson, Stephen J.; Hoerstrup, Simon P.; Goss, Ben G.; Haeberli, André; Aebli, Nikolaus
February 2008
Journal of Bone & Joint Surgery, American Volume;Feb2008, Vol. 90-A Issue 2, p349
Academic Journal
Background: Intraoperative cardiovascular deterioration as a result of pulmonary embolization of bone marrow fat is a potentially serious complication during vertebroplasty. The release of fatty material and thromboplastin from the bone marrow cavity during vertebroplasty may activate the coagulation cascade resulting in thrombogenesis, and pharmacological prophylaxis may therefore prevent cardiovascular complications. Thus, the effects of bone marrow fat embolism on coagulation activation during vertebroplasty were investigated with use of an animal model. Methods: Polymethylmethacrylate was injected into three lumbar vertebrae of six sheep in order to force bone marrow fat into the circulation. Invasive blood pressures and heart rate were recorded continuously until sixty minutes after the last injection. Cardiac output, arterial and mixed venous blood gas parameters, and coagulation parameters were measured at selected time-points. Postmortem lung biopsy specimens were assessed for the presence of intravascular fat. Results: Embolization of bone marrow fat resulted in a sudden and dramatic increase in mean pulmonary arterial pressure and a decrease in mean arterial blood pressure. There were no significant changes in any coagulation parameter from before the injection to after the injection. Intravascular fat and bone marrow cells were present in all lung lobes. Conclusions: Injection of polymethylmethacrylate into vertebral bodies caused embolization of bone marrow fat with subsequent transient cardiovascular deterioration, but no changes in coagulation parameters were observed. Thromboembolism did not contribute to the observed cardiovascular changes. Clinical Relevance: Cardiovascular complications as a result of bone marrow fat embolism should be considered in patients undergoing vertebroplasty. Vertebroplasty with use of polymethylmethacrylate does not appear to activate the coagulation system or cause thromboembolism.


Related Articles

  • Fat embolism syndrome. Kwiatt, Michael E.; Seamon, Mark J. // International Journal of Critical Illness & Injury Science;Jan-Mar2013, Vol. 3 Issue 1, p64 

    Fat embolism syndrome (FES) is an ill-defined clinical entity that arises from the systemic manifestations of fat emboli within the microcirculation. Embolized fat within capillary beds cause direct tissue damage as well as induce a systemic inflammatory response resulting in pulmonary,...

  • Long-term management of patients taking immunosuppressive drugs. Hsu, Denise C.; Katelaris, Constance H. // Australian Prescriber;Jun2009, Vol. 32 Issue 3, p68 

    The number of patients taking immunosuppressive drugs for the management of autoimmune inflammatory conditions is increasing. The general practitioner needs to be active in preventing, monitoring and managing the adverse effects of these drugs even long after the treatment has ceased. Monitoring...

  • In Vitro Interactions of Extracellular Histones with LDL Suggest a Potential Pro-Atherogenic Role. Pemberton, Alan D.; Brown, Jeremy K. // PLoS ONE;2010, Vol. 5 Issue 3, p1 

    Background: Nuclear histones have previously been shown to aggregate LDL in vitro, suggestive of a possible proatherogenic role. Recent studies indicate that histones are released during acute inflammation, and therefore might interact with circulating lipoproteins in vivo. In view of the...

  • Biological effects of stroma-derived factor-1α on normal and CML CD34+ haemopoietic cells. Dürig, J; Rosenthal, C; Elmaagacli, A; Heyworth, C; Halfmeyer, K; Kasper, C; Novotny, J; Dührsen, U // Leukemia (08876924);Sep2000, Vol. 14 Issue 9, p1652 

    We compared the biological effects of the CXC chemokine SDF-1α on immunomagnetically purified CD34[SUP+] cells isolated from human normal bone marrow (NBM), leukapheresis products (LP) and patients with chronic myeloid leukaemia (CML). LP CD34[SUP+] cells showed a significantly stronger...

  • Reply to Wheatley and Hills: interpretation of subgroups in the AML-BFM 93 study. Zimmermann, M; Creutzig, U // Leukemia (08876924);Nov2001, Vol. 15 Issue 11, p1804 

    Presents a letter in response to the letter on AML-BFM 93 study, published in the November 1, 2001 issue of the journal 'Leukemia'. Treatment of patients included in the study.

  • Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study. Wheatley, K; Hills, R K // Leukemia (08876924);Nov2001, Vol. 15 Issue 11, p1803 

    Presents a letter to the editor on the AML-BFM 93 study, published in the November 1, 2001 issue of the journal 'Leukemia'. Failure to achieve blast cell clearance within specified time periods.

  • Bone marrow match sought.  // Hudson Valley Business Journal;3/5/2012, Vol. 23 Issue 10, p3 

    The article presents information on the Bone Marrow Donor Drive, that will be held on March 17, 2012, in Poughkeepsie, New York.

  • hematosteon.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1036 

    A definition of the term "hematosteon," which refers to the bleeding into bone marrow, is presented.

  • inherited bone marrow failure syndromes.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1196 

    A reference entry for inherited bone marrow failure syndromes (IBMFS) is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics